Form 4: Synaptogenix Director Acquires Stock Options
SEC Form 4 Filing
Director Joshua Silverman of Synaptogenix, Inc. acquires stock options exercisable after one year of service.
Summary
- Joshua Silverman, a director of Synaptogenix, Inc., filed a Form 4 on April 10, 2024.
- The form reports a transaction that occurred on April 8, 2024, where Silverman acquired stock options.
- Silverman acquired options to purchase 800 shares of Synaptogenix common stock at an exercise price of $5.39 per share.
- The options vest and become exercisable after one year of service following April 8, 2024, and expire on April 8, 2034.
- Following the transaction, Silverman directly owns options for 800 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which can be seen as a positive sign of alignment between management and shareholders, but doesn't necessarily indicate a major shift in the company's prospects.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule implies continued service by the director.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a director's increased stake in the company, which is common practice.
Comparison to Industry Standards
- Stock option grants to directors are a common form of compensation in the biotechnology industry.
- The vesting schedule of one year is fairly standard.
- The specific number of options and exercise price would need to be compared to similar companies of Synaptogenix's size and stage to determine if it is in line with industry norms.
Stakeholder Impact
- The acquisition of stock options by a director can align the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/08/2024 | Date of the stock option transaction. |
| 04/08/2024 | Vesting start date for the stock options; options become exercisable after one year of service. |
| 04/08/2034 | Expiration date of the stock options. |
| 04/10/2024 | Date the Form 4 was filed. |
Keywords
Synaptogenix, Director, Stock Options, Form 4, SNPX, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.